GlassScriptPhysician profile
Kane Loux Schaphorst
NPI 1518901248
$5,799.92
in general payments reported to CMS, 2019-2025
40 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $476 · 2021: $589 · 2022: $961 · 2023: $928 · 2024: $1,077 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,206.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,711.71 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Janssen Pharmaceuticals, INC | $552.37 | 2019-2022 | |
| United Therapeutics Corporation | $547.86 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Regeneron Healthcare Solutions, INC. | $451.22 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $353.07 | 2019-2025 | Winrevair, Zerbaxa, Recarbrio |
| Bayer Healthcare Pharmaceuticals INC. | $260.54 | 2019-2024 | |
| Genzyme Corporation | $253.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $207.31 | 2019-2025 | Tezspire, Fasenra |
| Alexion Pharmaceuticals, INC. | $167.20 | 2019-2023 | Ultomiris |
| Astellas Pharma US INC | $153.76 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.28 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Electromed, INC. | $104.37 | 2019-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $95.94 | 2020-2022 | |
| Mylan Specialty L.P. | $69.74 | 2019-2024 | Yupelri |
| Sandoz INC. | $69.26 | 2021-2023 | Treprostinil |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $62.16 | 2023-2024 | |
| Abiomed | $51.70 | 2023-2024 | Impella |
| Ethicon INC. | $51.46 | 2022-2024 | Monarch Platform |
| E.R. Squibb & Sons, L.L.C. | $40.18 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $37.95 | 2019 | |
| Portola Pharmaceuticals, LLC | $33.26 | 2019-2020 | |
| Glaxosmithkline, LLC. | $32.60 | 2020-2023 | Trelegy Ellipta |
| Pfizer INC. | $29.93 | 2021-2024 | |
| Baxter Healthcare | $25.74 | 2022 | |
| Calliditas Therapeutics US INC. | $25.37 | 2025 | Tarpeyo |
| Liquidia Technologies, INC. | $22.96 | 2025 | Yutrepia |
| Eisai INC. | $21.07 | 2024 | |
| Inogen, INC. | $20.12 | 2022 | |
| Viatris Specialty LLC | $20.08 | 2025 | Yupelri |
| Greenwich Biosciences, INC. | $20.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.39 | 2019 | |
| Shionogi INC | $18.95 | 2023 | Fetroja |
| Ani Pharmaceuticals, INC. | $18.82 | 2024 | Purified Cortrophin Gel |
| Chiesi USA, INC. | $16.84 | 2021 | |
| Csl Behring | $15.76 | 2019 | |
| Sanofi Pasteur INC. | $14.17 | 2020 | |
| Genentech USA, INC. | $13.94 | 2019 | |
| Pulmonx Corporation | $12.93 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Covidien LP | $11.92 | 2020 | |
| Philips North America LLC | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kane Schaphorst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.